SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001136261-21-000094
Filing Date
2021-06-17
Accepted
2021-06-17 16:14:18
Documents
2
Period of Report
2021-06-14
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K body8k.htm 8-K 12669
2 ACKNOWLEDGMENT AND TERMINATION AGREEMENT exh10-1.htm EX-10.1 15644
  Complete submission text file 0001136261-21-000094.txt   29844
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 211024881
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences